After the pandemic: perspectives on the future trajectory of COVID-19

[1]  M. Beltramello,et al.  SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape , 2021, Nature.

[2]  Rajesh Gupta.  The need for global access to biomedical innovations during pandemics , 2021, Nature Biotechnology.

[3]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[4]  E. Wherry,et al.  Rapid induction of antigen-specific CD4+ T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination , 2021, bioRxiv.

[5]  M. Suchard,et al.  Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil , 2021, Science.

[6]  M. Singer,et al.  Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study , 2021, The Lancet Infectious Diseases.

[7]  A. Huppert,et al.  Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals , 2021, Nature Medicine.

[8]  D. Schwartz,et al.  Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[9]  A. Telenti,et al.  Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies , 2021, bioRxiv.

[10]  D. Larremore,et al.  Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination , 2021, Nature Reviews Immunology.

[11]  D. Stuart,et al.  Antibody evasion by the P.1 strain of SARS-CoV-2 , 2021, Cell.

[12]  J. Mellors,et al.  The emerging plasticity of SARS-CoV-2 , 2021, Science.

[13]  D. Fremont,et al.  A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques , 2021, Cell Reports Medicine.

[14]  J. Jaubert,et al.  The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice , 2021, bioRxiv.

[15]  S. Madhi,et al.  Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant , 2021, The New England Journal of Medicine.

[16]  P. Garred,et al.  The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization , 2021, Journal of Biological Chemistry.

[17]  E. Brown,et al.  Original Antigenic Sin: the Downside of Immunological Memory and Implications for COVID-19 , 2021, mSphere.

[18]  J. Todd,et al.  SARS-CoV-2 within-host diversity and transmission , 2021, Science.

[19]  D. Ho,et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.

[20]  D. Fremont,et al.  Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.

[21]  Sergei L. Kosakovsky Pond,et al.  Natural selection in the evolution of SARS-CoV-2 in bats created a generalist virus and highly capable human pathogen , 2021, PLoS biology.

[22]  C. Aschwanden.  Five reasons why COVID herd immunity is probably impossible , 2021, Nature.

[23]  M. Beer,et al.  SARS-CoV-2 spike D614G change enhances replication and transmission , 2021, Nature.

[24]  James D. Allen,et al.  Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection , 2021, Cell.

[25]  D. Lauffenburger,et al.  Humoral signatures of protective and pathological SARS-CoV-2 infection in children , 2021, Nature Medicine.

[26]  H. Jäck,et al.  SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization , 2021, bioRxiv.

[27]  Lisa E. Gralinski,et al.  SARS-CoV-2 Infection is Effectively Treated and Prevented by EIDD-2801 , 2021, Nature.

[28]  Brent S. Pedersen,et al.  Extensive recombination-driven coronavirus diversification expands the pool of potential pandemic pathogens , 2021, bioRxiv.

[29]  M. Kamarck,et al.  Process and operations strategies to enable global access to antibody therapies , 2021, Biotechnology progress.

[30]  Joshua B. Singer,et al.  Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study , 2021, The Lancet. Public health.

[31]  D. Rader,et al.  Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection , 2021, Cell.

[32]  M. Beltramello,et al.  Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity , 2021, Cell.

[33]  D. Ho,et al.  Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.

[34]  D. Fremont,et al.  A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques , 2021, bioRxiv.

[35]  A. García-Sastre,et al.  The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera , 2021, medRxiv.

[36]  O. Bjørnstad,et al.  Immunological characteristics govern the transition of COVID-19 to endemicity , 2021, Science.

[37]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[38]  B. Bosch,et al.  Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors , 2021, medRxiv.

[39]  Carl A. B. Pearson,et al.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[40]  J. Bloom,et al.  A human coronavirus evolves antigenically to escape antibody immunity , 2020, bioRxiv.

[41]  H. V. Bakel,et al.  A household case evidences shorter shedding of SARS-CoV-2 in naturally infected cats compared to their human owners , 2020, Emerging microbes & infections.

[42]  U. Agrimi,et al.  Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy , 2020, Nature communications.

[43]  R. Gupta.  Advancing new tools for infectious diseases , 2020, Science.

[44]  M. Nussenzweig,et al.  Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo , 2020, The Journal of experimental medicine.

[45]  M. Koopmans,et al.  Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans , 2020, Science.

[46]  D. Rader,et al.  Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection , 2020, medRxiv.

[47]  E. Holmes,et al.  A household case evidences shorter shedding of SARS-CoV-2 in naturally infected cats compared to their human owners. , 2020, medRxiv.

[48]  M. Beltramello,et al.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.

[49]  Sarah K. Hilton,et al.  Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding , 2020, Cell.

[50]  G. De Serres,et al.  Common human coronaviruses seem at least as severe as influenza in patients hospitalized with acute respiratory infection: results from 8-year hospital-based surveillance in Quebec, Canada , 2020, The Journal of infectious diseases.

[51]  D. A. Jackson,et al.  Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity , 2020, Cell.

[52]  Yan Li,et al.  Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy , 2020, Science.

[53]  S. Tong,et al.  From People to Panthera: Natural SARS-CoV-2 Infection in Tigers and Lions at the Bronx Zoo , 2020, mBio.

[54]  L. Yang,et al.  Comparing COVID-19 and the 1918–19 influenza pandemics in the United Kingdom , 2020, International Journal of Infectious Diseases.

[55]  Jesse D. Bloom,et al.  Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding , 2020, bioRxiv.

[56]  G. Atwal,et al.  Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies , 2020, Science.

[57]  M. Koopmans,et al.  SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[58]  Rachel E. Baker,et al.  Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic , 2020, Science.

[59]  P. Lemey,et al.  Temporal signal and the phylodynamic threshold of SARS-CoV-2 , 2020, bioRxiv.

[60]  M. Koopmans,et al.  SARS-CoV-2 is transmitted via contact and via the air between ferrets , 2020, bioRxiv.

[61]  Chonggang Xu,et al.  High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.

[62]  Rob Phillips,et al.  SARS-CoV-2 (COVID-19) by the numbers , 2020, eLife.

[63]  D. Chu,et al.  Canine SARS-CoV-2 infection , 2020, Nature.

[64]  Yonatan H. Grad,et al.  Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.

[65]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[66]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[67]  M. Letko,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[68]  D. Griffin.  Measles-vaccine , 2020, Reactions Weekly.

[69]  Cecile Viboud,et al.  Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project , 2019, Journal of global health.

[70]  George Georgiou,et al.  Persistent Antibody Clonotypes Dominate the Serum Response to Influenza over Multiple Years and Repeated Vaccinations. , 2019, Cell host & microbe.

[71]  S. Swain,et al.  Original Antigenic Sin: Friend or Foe in Developing a Broadly Cross-Reactive Vaccine to Influenza? , 2019, Cell host & microbe.

[72]  T. Scott,et al.  Measles vaccine , 2018, Reactions Weekly.

[73]  E. Holmes,et al.  The phylogenomics of evolving virus virulence , 2018, Nature Reviews Genetics.

[74]  Nam Joong Kim,et al.  Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea , 2018, The Korean journal of internal medicine.

[75]  P. Quinlisk,et al.  Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control , 2017, The New England journal of medicine.

[76]  Edward C. Holmes,et al.  Human Adaptation of Ebola Virus during the West African Outbreak , 2016, Cell.

[77]  M. Clerici,et al.  Molecular Evolution of Human Coronavirus Genomes , 2016, Trends in Microbiology.

[78]  K. Subbarao,et al.  Influenza vaccines: challenges and solutions. , 2015, Cell host & microbe.

[79]  M. Denison,et al.  Thinking Outside the Triangle: Replication Fidelity of the Largest RNA Viruses. , 2014, Annual review of virology.

[80]  D. van Baarle,et al.  T Cell Responses to Viral Infections – Opportunities for Peptide Vaccination , 2014, Front. Immunol..

[81]  E. Holmes,et al.  Global transmission of influenza viruses from humans to swine. , 2012, The Journal of general virology.

[82]  Theo M Bestebroer,et al.  Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets , 2012, Science.

[83]  M. Levin,et al.  The rationale for quadrivalent influenza vaccines , 2012, Human vaccines & immunotherapeutics.

[84]  M. Eichelberger,et al.  Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses , 2011, Proceedings of the National Academy of Sciences.

[85]  Christopher W. Wong,et al.  Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. , 2010, The New England journal of medicine.

[86]  A. García-Sastre,et al.  Protection of Mice against Lethal Challenge with 2009 H1N1 Influenza A Virus by 1918-Like and Classical Swine H1N1 Based Vaccines , 2010, PLoS pathogens.

[87]  A. Fauci,et al.  The persistent legacy of the 1918 influenza virus. , 2009, The New England journal of medicine.

[88]  S. Plotkin.  The history of rubella and rubella vaccination leading to elimination. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  K. Reisinger,et al.  Ten year follow-up of healthy children who received one or two injections of varicella vaccine , 2004, The Pediatric infectious disease journal.

[90]  L. Webb,et al.  An ecological study. , 1979, Science.

[91]  D. Blayney,et al.  Challenges and solutions. , 2007, Journal of oncology practice.

[92]  A. Arvin,et al.  Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. , 1995, The Journal of infectious diseases.